Cibus (CBUS) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cibus (CBUS) has outperformed TuHURA Biosciences (HURA) over the past year, gaining 3.3% versus a loss of 24.0%. Over five years, CBUS leads with a -98.9% price change compared with -99.9% for HURA. TuHURA Biosciences is the larger company by market cap ($124.9 million vs $118.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBUS | HURA |
|---|---|---|
| Share price | $1.55 | $1.96 |
| Market cap | $118.46M | $124.90M |
| 1-day change | -2.52% | +1.55% |
| YTD return | -10.92% | +158.92% |
| 1-year return | +3.33% | -24.03% |
| 5-year return | -98.95% | -99.87% |
| EPS (TTM) | $-1.62 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.19 | $3.43 |
| 52-week low | $1.09 | $0.41 |
| Distance from 52-week high | -63.02% | -42.86% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +824.52% | +310.20% |
| Average volume | 186.50K | 244.46K |
| Shares outstanding | 76.43M | 63.73M |
| Employees | 118 | 22 |
| Sector | Industrials | Health Care |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBUS has outperformed HURA by 27.4 percentage points over the past year.
- The two companies sit in different sectors: Cibus in Industrials and TuHURA Biosciences in Health Care.
About Cibus
CBUS stock →Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits.
Industrials · Agricultural Chemicals · 118 employees
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
CBUS vs HURA FAQ
Which is bigger, Cibus or TuHURA Biosciences?
TuHURA Biosciences (HURA) is larger, with a market capitalization of $124.90M compared with $118.46M for Cibus (CBUS).
Which stock has performed better over the past year, CBUS or HURA?
CBUS returned +3.33% over the past 12 months, compared with -24.03% for HURA (price return, excluding dividends). Past performance does not predict future results.
Are Cibus and TuHURA Biosciences in the same industry?
No. Cibus is in the Industrials sector, while TuHURA Biosciences is in Health Care.